Ocular Hypotensive Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients with Glaucoma or Ocular Hypertension

Louis Cantor, Darrell WuDunn, Arnold Cortes, Joni Hoop, Stephenie Knotts

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: To evaluate the IOP-lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocular hypertension. Methods: Randomized, investigator-masked, parallel-group clinical trial. After completing a washout from all glaucoma medications, patients (n = 26) were randomized to bimatoprost or travoprost for 6 months. Visits were at baseline, week 1, and months 1, 3, and 6. IOP was measured at 9 AM at each visit and also at 1 and 4 PM at baseline and months 3 and 6. Results: At the baseline visit, there were no significant between-group differences in IOP at 9 AM, 1 PM, or 4 PM (P≥.776). After 6 months of therapy, both medications provided significant mean reductions from baseline IOP at every time point (P≤.007). Mean IOP reductions ranged from 7.4 mm Hg to 8.8 mm Hg (34% to 36%) with bimatoprost and from 4.6 mm Hg to 7.2 mm Hg (19% to 29%) with travoprost (P≥.057) after 6 months of medication. At the final study visit, more patients achieved low target pressures with bimatoprost than with travoprost at each time point. Both study medications were well tolerated and ocular redness was the most commonly reported adverse event in both treatment groups. Conclusion: Although both bimatoprost and travoprost effectively lowered IOP in patients with glaucoma or ocular hypertension, bimatoprost provided larger mean IOP reductions than travoprost. More patients achieved low target pressures with bimatoprost than with travoprost. The between-group differences were not statistically significant due to the small sample size. These findings are being further evaluated in an ongoing multicenter clinical trial.

Original languageEnglish
JournalSurvey of Ophthalmology
Volume49
Issue number2 SUPPL. 1
DOIs
StatePublished - Mar 2004

Fingerprint

Ocular Hypertension
Glaucoma
Clinical Trials
Pressure
Travoprost
Bimatoprost
Sample Size
Multicenter Studies
Therapeutics
Research Personnel

Keywords

  • Bimatoprost
  • Glaucoma
  • Intraocular pressure
  • Ocular hypertension
  • Target pressures
  • Travoprost

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ocular Hypotensive Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients with Glaucoma or Ocular Hypertension. / Cantor, Louis; WuDunn, Darrell; Cortes, Arnold; Hoop, Joni; Knotts, Stephenie.

In: Survey of Ophthalmology, Vol. 49, No. 2 SUPPL. 1, 03.2004.

Research output: Contribution to journalArticle

Cantor, Louis ; WuDunn, Darrell ; Cortes, Arnold ; Hoop, Joni ; Knotts, Stephenie. / Ocular Hypotensive Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients with Glaucoma or Ocular Hypertension. In: Survey of Ophthalmology. 2004 ; Vol. 49, No. 2 SUPPL. 1.
@article{025d8bdfd6b945608a428af4a941b980,
title = "Ocular Hypotensive Efficacy of Bimatoprost 0.03{\%} and Travoprost 0.004{\%} in Patients with Glaucoma or Ocular Hypertension",
abstract = "Purpose: To evaluate the IOP-lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocular hypertension. Methods: Randomized, investigator-masked, parallel-group clinical trial. After completing a washout from all glaucoma medications, patients (n = 26) were randomized to bimatoprost or travoprost for 6 months. Visits were at baseline, week 1, and months 1, 3, and 6. IOP was measured at 9 AM at each visit and also at 1 and 4 PM at baseline and months 3 and 6. Results: At the baseline visit, there were no significant between-group differences in IOP at 9 AM, 1 PM, or 4 PM (P≥.776). After 6 months of therapy, both medications provided significant mean reductions from baseline IOP at every time point (P≤.007). Mean IOP reductions ranged from 7.4 mm Hg to 8.8 mm Hg (34{\%} to 36{\%}) with bimatoprost and from 4.6 mm Hg to 7.2 mm Hg (19{\%} to 29{\%}) with travoprost (P≥.057) after 6 months of medication. At the final study visit, more patients achieved low target pressures with bimatoprost than with travoprost at each time point. Both study medications were well tolerated and ocular redness was the most commonly reported adverse event in both treatment groups. Conclusion: Although both bimatoprost and travoprost effectively lowered IOP in patients with glaucoma or ocular hypertension, bimatoprost provided larger mean IOP reductions than travoprost. More patients achieved low target pressures with bimatoprost than with travoprost. The between-group differences were not statistically significant due to the small sample size. These findings are being further evaluated in an ongoing multicenter clinical trial.",
keywords = "Bimatoprost, Glaucoma, Intraocular pressure, Ocular hypertension, Target pressures, Travoprost",
author = "Louis Cantor and Darrell WuDunn and Arnold Cortes and Joni Hoop and Stephenie Knotts",
year = "2004",
month = "3",
doi = "10.1016/j.survophthal.2003.12.015",
language = "English",
volume = "49",
journal = "Survey of Ophthalmology",
issn = "0039-6257",
publisher = "Elsevier USA",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Ocular Hypotensive Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients with Glaucoma or Ocular Hypertension

AU - Cantor, Louis

AU - WuDunn, Darrell

AU - Cortes, Arnold

AU - Hoop, Joni

AU - Knotts, Stephenie

PY - 2004/3

Y1 - 2004/3

N2 - Purpose: To evaluate the IOP-lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocular hypertension. Methods: Randomized, investigator-masked, parallel-group clinical trial. After completing a washout from all glaucoma medications, patients (n = 26) were randomized to bimatoprost or travoprost for 6 months. Visits were at baseline, week 1, and months 1, 3, and 6. IOP was measured at 9 AM at each visit and also at 1 and 4 PM at baseline and months 3 and 6. Results: At the baseline visit, there were no significant between-group differences in IOP at 9 AM, 1 PM, or 4 PM (P≥.776). After 6 months of therapy, both medications provided significant mean reductions from baseline IOP at every time point (P≤.007). Mean IOP reductions ranged from 7.4 mm Hg to 8.8 mm Hg (34% to 36%) with bimatoprost and from 4.6 mm Hg to 7.2 mm Hg (19% to 29%) with travoprost (P≥.057) after 6 months of medication. At the final study visit, more patients achieved low target pressures with bimatoprost than with travoprost at each time point. Both study medications were well tolerated and ocular redness was the most commonly reported adverse event in both treatment groups. Conclusion: Although both bimatoprost and travoprost effectively lowered IOP in patients with glaucoma or ocular hypertension, bimatoprost provided larger mean IOP reductions than travoprost. More patients achieved low target pressures with bimatoprost than with travoprost. The between-group differences were not statistically significant due to the small sample size. These findings are being further evaluated in an ongoing multicenter clinical trial.

AB - Purpose: To evaluate the IOP-lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocular hypertension. Methods: Randomized, investigator-masked, parallel-group clinical trial. After completing a washout from all glaucoma medications, patients (n = 26) were randomized to bimatoprost or travoprost for 6 months. Visits were at baseline, week 1, and months 1, 3, and 6. IOP was measured at 9 AM at each visit and also at 1 and 4 PM at baseline and months 3 and 6. Results: At the baseline visit, there were no significant between-group differences in IOP at 9 AM, 1 PM, or 4 PM (P≥.776). After 6 months of therapy, both medications provided significant mean reductions from baseline IOP at every time point (P≤.007). Mean IOP reductions ranged from 7.4 mm Hg to 8.8 mm Hg (34% to 36%) with bimatoprost and from 4.6 mm Hg to 7.2 mm Hg (19% to 29%) with travoprost (P≥.057) after 6 months of medication. At the final study visit, more patients achieved low target pressures with bimatoprost than with travoprost at each time point. Both study medications were well tolerated and ocular redness was the most commonly reported adverse event in both treatment groups. Conclusion: Although both bimatoprost and travoprost effectively lowered IOP in patients with glaucoma or ocular hypertension, bimatoprost provided larger mean IOP reductions than travoprost. More patients achieved low target pressures with bimatoprost than with travoprost. The between-group differences were not statistically significant due to the small sample size. These findings are being further evaluated in an ongoing multicenter clinical trial.

KW - Bimatoprost

KW - Glaucoma

KW - Intraocular pressure

KW - Ocular hypertension

KW - Target pressures

KW - Travoprost

UR - http://www.scopus.com/inward/record.url?scp=1542328114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542328114&partnerID=8YFLogxK

U2 - 10.1016/j.survophthal.2003.12.015

DO - 10.1016/j.survophthal.2003.12.015

M3 - Article

C2 - 15016557

AN - SCOPUS:1542328114

VL - 49

JO - Survey of Ophthalmology

JF - Survey of Ophthalmology

SN - 0039-6257

IS - 2 SUPPL. 1

ER -